• 1
    Office of Applied Studies. Overview of Findings from the 2003 National Survey on Drug Use and Health. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2004.
  • 2
    McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 2000; 284: 16891695.
  • 3
    Amato L, Davoli M, Perucci CA, Ferri M, Faggiano F, Mattick RP. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat 2005; 28: 321329.
  • 4
    Gowing L, Farrell M, Bornemann R, Ali R. Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev 2008; (2): CD004145.
  • 5
    Termorshuizen F, Krol A, Prins M, Geskus R, van den Brink W, van Ameijden EJ. Prediction of relapse to frequent heroin use and the role of methadone prescription: an analysis of the Amsterdam Cohort Study among drug users. Drug Alcohol Depend 2005; 79: 231240.
  • 6
    Corsi KF, Lehman WK, Booth RE. The effect of methadone maintenance on positive outcomes for opiate injection drug users. J Subst Abuse Treat 2009; 37: 120126.
  • 7
    Bobes Garcia J, Bobes Bascaran MT. [Long term effectiveness of methadone maintenance treatments in persons with addiction to opiates]. Adicciones 2012; 24: 179183.
  • 8
    Grella CE, Lovinger K. Gender differences in physical and mental health outcomes among an aging cohort of individuals with a history of heroin dependence. Addict Behav 2012; 37: 306312.
  • 9
    Davstad I, Stenbacka M, Leifman A, Beck O, Korkmaz S, Romelsjo A. Patterns of illicit drug use and retention in a methadone program: a longitudinal study. J Opioid Manag 2007; 3: 2734.
  • 10
    Comiskey CM, Cox G. Analysis of the impact of treatment setting on outcomes from methadone treatment. J Subst Abuse Treat 2010; 39: 195201.
  • 11
    Peles E, Schreiber S, Adelson M. Factors predicting retention in treatment: 10-year experience of a methadone maintenance treatment (MMT) clinic in Israel. Drug Alcohol Depend 2006; 82: 211217.
  • 12
    Astals M, Diaz L, Domingo-Salvany A, Martin-Santos R, Bulbena A, Torrens M. Impact of co-occurring psychiatric disorders on retention in a methadone maintenance program: an 18-month follow-up study. Int J Environ Res Public Health 2009; 6: 28222832.
  • 13
    Fernandez-Miranda JJ, Gonzalez Garcia-Portilla MP, Saiz Martinez PA, Gutierrez Cienfuegos E, Bobes Garcia J. Retencion a los 6 años en un programa de mantenimiento con metadona y variables relacionadas. Rev Esp Drogodepend 2001; 26: 4356.
  • 14
    Gossop M, Stewart D, Browne N, Marsden J. Methadone treatment for opiate dependent patients in general practice and specialist clinic settings: outcomes at 2-year follow-up. J Subst Abuse Treat 2003; 24: 313321.
  • 15
    Fernandez-Miranda JJ, Gonzalez Garcia-Portilla MP, Saiz Martinez PA, Gutierrez Cienfuegos E, Bobes Garcia J. Consumo de drogas ilegales y alcohol antes y a lo largo de 6 años de mantenimiento con metadona y variables relacionadas. Adicciones 2001; 13: 179188.
  • 16
    Fernandez-Miranda JJ, Gonzalez Garcia-Portilla MP, Saiz Martinez PA, Gutierrez Cienfuegos E, Bobes Garcia J. Influencia de los trastornos psiquiátricos en la efectividad de un programa de mantenimiento prolongado con metadona. Actas Esp Psiquiatr 2001; 29: 228232.
  • 17
    Coviello DM, Zanis DA, Wesnoski SA, Lynch KG, Drapkin M. Characteristics and 9-month outcomes of discharged methadone maintenance clients. J Subst Abuse Treat 2011; 40: 165174.
  • 18
    Gossop M, Marsden J, Stewart D, Kidd T. Reduction or cessation of injecting risk behaviours? Treatment outcomes at 1-year follow-up. Addict Behav 2003; 28: 785793.
  • 19
    Cacciola JS, Alterman AI, Rutherford MJ, McKay JR, Mulvaney FD. The relationship of psychiatric comorbidity to treatment outcomes in methadone maintained patients. Drug Alcohol Depend 2001; 61: 271280.
  • 20
    Deck D, Wiitala W, McFarland B, Campbell K, Mullooly J, Krupski A, McCarty D. Medicaid coverage, methadone maintenance, and felony arrests: outcomes of opiate treatment in two states. J Addict Dis 2009; 28: 89102.
  • 21
    Litchfield J, Maronge A, Rigg T, Rees B, Harshey R, Keen J. Can a targeted GP-led clinic improve outcomes for street sex workers who use heroin? Br J Gen Pract 2010; 60: 514516.
  • 22
    Curcio F, Franco T, Topa M, Baldassarre C. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey. Eur Rev Med Pharmacol Sci 2011; 15: 871874.
  • 23
    Soeffing JM, Martin LD, Fingerhood MI, Jasinski DR, Rastegar DA. Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year. J Subst Abuse Treat 2009; 37: 426430.
  • 24
    Parran TV, Adelman CA, Merkin B, Pagano ME, Defranco R, Ionescu RA, Mace AG. Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy. Drug Alcohol Depend 2010; 106: 5660.
  • 25
    Altice FL, Bruce RD, Lucas GM, Lum PJ, Korthuis PT, Flanigan TP, Cunningham CO, Sullivan LE, Vergara-Rodriguez P, Fiellin DA, Cajina A, Botsko M, Nandi V, Gourevitch MN, Finkelstein R. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr 2011; 56: (Suppl. 1): S2232.
  • 26
    Strang J, Groshkova T, Metrebian N. EMCDDA INSIGHTS. New Heroin-Assisted Treatment. Recent Evidence and Current Practices of Supervised Injectable Heroin Treatment in Europe and beyond. Luxembourg: Publications Office of the European Union, 2012.
  • 27
    Oviedo-Joekes E, Nosyk B, Brissette S, Chettiar J, Schneeberger P, Marsh DC, Krausz M, Anis A, Schechter MT. The North American Opiate Medication Initiative (NAOMI): profile of participants in North America's first trial of heroin-assisted treatment. J Urban Health 2008; 85: 812825.
  • 28
    Blanken P, Hendriks VM, van Ree JM, van den Brink W. Outcome of long-term heroin-assisted treatment offered to chronic, treatment-resistant heroin addicts in the Netherlands. Addiction 2010; 105: 300308.
  • 29
    Oviedo-Joekes E, Guh D, Brissette S, Marchand K, Marsh D, Chettiar J, Nosyk B, Krausz M, Anis A, Schechter MT. Effectiveness of diacetylmorphine versus methadone for the treatment of opioid dependence in women. Drug Alcohol Depend 2010; 111: 5057.
  • 30
    March JC, Oviedo-Joekes E, Perea-Milla E, Carrasco F. Controlled trial of prescribed heroin in the treatment of opioid addiction. J Subst Abuse Treat 2006; 31: 203211.
  • 31
    Haasen C, Verthein U, Degkwitz P, Berger J, Krausz M, Naber D. Heroin-assisted treatment for opioid dependence: randomised controlled trial. Br J Psychiatry 2007; 191: 5562.
  • 32
    Blanken P, Hendriks VM, Koeter MW, van Ree JM, van den Brink W. Craving and illicit heroin use among patients in heroin-assisted treatment. Drug Alcohol Depend 2012; 120: 7480.
  • 33
    Strang J, Metrebian N, Lintzeris N, Potts L, Carnwath T, Mayet S, Williams H, Zador D, Evers R, Groshkova T, Charles V, Martin A, Forzisi L. Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): a randomised trial. Lancet 2010; 375: 18851895.
  • 34
    Glanz M, Klawansky S, McAullife W, Chalmers T. Methadone vs. L-alpha-acetylmethadol (LAAM) in the treatment of opiate addiction. A meta-analysis of the randomized, controlled trials. Am J Addict 1997; 6: 339349.
  • 35
    European Agency for the Evaluation of Medicinal Products. EMEA Public Statement on the Recommendation to Suspend the Marketing Authorisation for Orlaam (Levacetylmethadol) in the European Union. London: EMEA, 2001.
  • 36
    Jaffe JH, O'Keeffe C. From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States. Drug Alcohol Depend 2003; 70: S311.
  • 37
    World Health Organization. Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. Washington, DC: World Health Organization, 2009.
  • 38
    Viswanath B, Chand P, Benegal V, Murthy P. Agonist treatment in opioid use: advances and controversy. Asian J Psychiatr 2012; 5: 125131.
  • 39
    Soyka M, Kranzler HR, van den Brink W, Krystal J, Moller HJ, Kasper S. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: opioid dependence. World J Biol Psychiatry 2011; 12: 160187.
  • 40
    Kraus ML, Alford DP, Kotz MM, Levounis P, Mandell TW, Meyer M, Salsitz EA, Wetterau N, Wyatt SA. Statement of the American Society of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction. J Addict Med 2011; 5: 254263.
  • 41
    Ducharme S, Fraser R, Gill K. Update on the clinical use of buprenorphine: in opioid-related disorders. Can Fam Physician 2012; 58: 3741.
  • 42
    Saxon AJ, McCarty D. Challenges in the adoption of new pharmacotherapeutics for addiction to alcohol and other drugs. Pharmacol Ther 2005; 108: 119128.
  • 43
    Dunn KE, Sigmon SC, Strain EC, Heil SH, Higgins ST. The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review. Drug Alcohol Depend 2011; 119: 19.
  • 44
    PRNewswire. Reckitt Benckiser Pharmaceuticals Inc. submits citezen petition to U.S. FDA resquesting action to mitigate risk of pediatric exposure with opioid dependence treatment. 2012.
  • 45
    Rehm J, Fischer B. Should heroin be prescribed to heroin misusers? Yes. BMJ 2008; 336: 70.
  • 46
    McKeganey N. Should heroin be prescribed to heroin misusers? No. BMJ 2008; 336: 71.
  • 47
    Jimenez-Trevino L, Saiz PA, Garcia-Portilla MP, Diaz-Mesa EM, Sanchez-Lasheras F, Buron P, Casares MJ, Marina P, Gutierrez E, Bobes J. A 25-year follow-up of patients admitted to methadone treatment for the first time: mortality and gender differences. Addict Behav 2011; 36: 11841190.
  • 48
    Rehm J, Frick U, Hartwig C, Gutzwiller F, Gschwend P, Uchtenhagen A. Mortality in heroin-assisted treatment in Switzerland 1994–2000. Drug Alcohol Depend 2005; 79: 137143.
  • 49
    Eiroa-Orosa FJ, Verthein U, Kuhn S, Lindemann C, Karow A, Haasen C, Reimer J. Implication of gender differences in heroin-assisted treatment: results from the German randomized controlled trial. Am J Addict 2010; 19: 312318.
  • 50
    Blanken P, Hendriks VM, Koeter MW, van Ree JM, van den Brink W. Matching of treatment-resistant heroin-dependent patients to medical prescription of heroin or oral methadone treatment: results from two randomized controlled trials. Addiction 2005; 100: 8995.